System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Interventional Recruiting

NCT05641142 on ClinicalTrials.gov

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

  • Sponsor: Centre Hospitalier Universitaire de Clermont-Ferrand
  • Enrollment: 100 (Estimated)
  • Study start: 2023-04-07 (Actual)
  • Primary completion: 2029-04-01 (Estimated)
  • Study completion: 2029-04-01 (Estimated)
  • Allocation: N/a
  • InterventionModel: Single Group
  • InterventionModelDescription: cohort study
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).

Conditions

  • Hereditary Hemorrhagic Telangiectasia
  • Rendu Osler Disease

Intervention / Treatment

  • Other: monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease

Primary Outcome Measures

  • Number of transfusions and/or intravenous iron (3 months after exposure to anticoagulants and/or antiplatelet)
    Number of transfusions and/or intravenous iron before (3 months) and within 3 months after exposure to anticoagulants and/or antiplatelet in patients with Rendu-Osler disease.

Countries

France

Locations and Investigators

  • CHU d'Angers, Angers, France (Recruiting)
    • Lise Laclautre
    • Christian LAVIGNE (Principal Investigator)
  • CHU de Bordeaux, Bordeaux, France (Recruiting)
    • Lise Laclautre
    • Pierre DUFFAU (Principal Investigator)
  • Hôpital Ambroise Paré, Boulogne-Billancourt, France (Not yet recruiting)
    • Lise Laclautre
    • Sandra Blivet
  • CHU de Caen Normandie, Caen, France (Recruiting)
    • Lise Laclautre
    • Laurent Chaussavoine (Principal Investigator)
  • CHU clermont-ferrand, Clermont-Ferrand, France (Recruiting)
    • Lise Laclautre
    • Vincent GROBOST (Principal Investigator)
  • CHU de Dijon, Dijon, France (Recruiting)
    • Lise Laclautre
    • Hélène GREIGERT (Principal Investigator)
  • CHRU de Lille, Lille, France (Not yet recruiting)
    • Lise Laclautre
    • Hélène Maillard (Principal Investigator)
  • Hospices Civiles de Lyon, Lyon, France (Recruiting)
    • Lise Laclautre
    • Sophie Dupuis-Girod (Principal Investigator)
  • Assistance Publique - Hôpitaux de Marseille, Marseille, France (Not yet recruiting)
    • Lise Laclautre
    • Baptiste André (Principal Investigator)
  • CHU de Montpellier, Montpellier, France (Recruiting)
    • Lise Laclautre
    • Sophie Rivière (Principal Investigator)
  • CHU de Nancy, Nancy, France (Recruiting)
    • Lise Laclautre
    • Shirine MOHAMED (Principal Investigator)
  • CHU de Nantes, Nantes, France (Recruiting)
    • Lise Laclautre
    • Giovanni Gautier (Principal Investigator)
  • CHU de Nice, Nice, France (Recruiting)
    • Lise Laclautre
    • Johana PRADELLI (Principal Investigator)
  • AP-HP - Hôpital Ténon, Paris, France (Recruiting)
    • Lise Laclautre
    • Michel DJIBRE (Principal Investigator)
  • CHU de Poitiers, Poitiers, France (Not yet recruiting)
    • Lise Laclautre
    • Xavier Le Guillou Horn (Principal Investigator)
  • CHU de Rennes, Rennes, France (Recruiting)
    • Lise Laclautre
    • Mallorie KERJOUAN (Principal Investigator)
  • CHRU de Strasbourg, Strasbourg, France (Recruiting)
    • Lise Laclautre
    • Murielle RONDEAU-LUTZ (Principal Investigator)
  • CHU de Toulouse, Toulouse, France (Not yet recruiting)
    • Lise Laclautre
    • Laurent Alric (Principal Investigator)

Study Officials